{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Melika ET"],"pubmed_abstract":["<h4>Background</h4>IFN-gamma (IFN-γ) signaling influences myocardial inflammation and fibrosis across a wide range of conditions, including ischemic and non-ischemic heart failure (HF). However, the direct effects of IFN-γ on cardiomyocytes remain poorly understood. Here, we developed a novel in vivo model to investigate how IFN-γ impacts myocardial metabolism and function.<h4>Methods</h4>Male C57BL/6J mice were injected intravenously with hepatotropic adeno-associated virus (AAV2/8) carrying <i>Ifng</i> and <i>nLuc</i> reporter under the albumin promoter (AAV-<i>Ifng</i>) or empty vector control virus (AAV-ctrl). Cardiac alterations were monitored on day 28 through flow cytometry, bulk RNA sequencing, targeted metabolomics, isolated mitochondrial activity, echocardiography, and in vivo im"],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2025.08.31.673391"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12424622"],"repository":["biostudies-literature"],"pubmed_title":["Interferon gamma signaling drives cardiac metabolic rewiring."],"pmcid":["PMC12424622"],"pubmed_authors":["Kuhn M","Hofmann U","Vath M","Karlstaedt A","Nickel A","Kim K","Arampatzi P","Melika ET","Higuchi T","Frantz S","Maack C","Ramos GC","Arias-Loza P","Gasteiger G","Srivastava M","Chen X","Cunha E","Ashour D"],"additional_accession":[]},"is_claimable":false,"name":"Interferon gamma signaling drives cardiac metabolic rewiring.","description":"<h4>Background</h4>IFN-gamma (IFN-γ) signaling influences myocardial inflammation and fibrosis across a wide range of conditions, including ischemic and non-ischemic heart failure (HF). However, the direct effects of IFN-γ on cardiomyocytes remain poorly understood. Here, we developed a novel in vivo model to investigate how IFN-γ impacts myocardial metabolism and function.<h4>Methods</h4>Male C57BL/6J mice were injected intravenously with hepatotropic adeno-associated virus (AAV2/8) carrying <i>Ifng</i> and <i>nLuc</i> reporter under the albumin promoter (AAV-<i>Ifng</i>) or empty vector control virus (AAV-ctrl). Cardiac alterations were monitored on day 28 through flow cytometry, bulk RNA sequencing, targeted metabolomics, isolated mitochondrial activity, echocardiography, and in vivo im","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-26T20:05:58.759Z","creation":"2026-05-26T03:06:36.7Z"},"accession":"S-EPMC12424622","cross_references":{"pubmed":["40950099"],"doi":["10.1101/2025.08.31.673391"]}}